Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Germany / NCT04442789
Recruiting Observational

Sequelae of Sars-CoV-2 Infections

NCT04442789 · tracked via the Priya Life Science Germany tracker
Sponsor
University of Giessen
Phase
Observational
Started
2020-05-20
Last updated
2025-03-30

Condition(s) studied

Lung DiseasesCardiac DiseaseInflammatory Reaction

Study summary

By the end of 2019 a new coronavirus, named SARS-CoV-2, was discovered in patients with pneumonia in Wuhan, China. In the following weeks and months the virus spread globally, having a tremendous impact on global health and economy. To date, no vaccine or therapy is available. Severe courses of the infection not only affect the lungs, but also other organs like the heart, kidney, or liver. The lack of preexisting immunity might at least partially explain the affection of extra pulmonary organs not yet seen in infections due to other respiratory viruses. In this observational investigation the study group will follow up on patients that have been hospitalized due to a SARS-CoV-2 infection, and monitor sequelae in various organs, with an emphasis on the pulmo-cardiovascular system. Our that in some patients, organ damage will persist and require long-term medical care.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * hospitalization due to Sars-CoV-2 infection Exclusion Criteria: * under 18 years of age

Primary outcome measure(s)

  • Sequelae after COVID-19 — 12 months, extension if required
    Identify organ dysfunction after SARS-CoV-2 infections

Trial sites (1)

FacilityCityRegionStatus
Department of Internal Medicine II, Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Justus-Liebig-University Giessen Germany Recruiting

More University of Giessen trials in Germany

Giessen Stroke Registry Recruiting
Endtidal Carbon Dioxide for Earlier Detection of Pulmonary Hypertension Enrolling by invitation
Pulmonary Vascular Dysfunction as a Cause of Persistent Exertional Dyspnea After Coronavirus Disease (COVID-19) Active, not recruiting
Non-invasive Measurement of the Hypotension Prediction Index for the Reduction of Intraoperative Hypotension Recruiting
Giessen Pulmonary Hypertension Registry and Biobank Recruiting

Other trials for the same condition

A Study of Mosliciguat in PH-ILD Active, not recruiting
BoStOn SCientific Rhythm MAnagemenT REgiStry Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04442789 on ClinicalTrials.gov ↗ ← All trials in Germany